secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-10-08T12:30:37+00:00
Accession:  0001493152-26-046266
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity Technologies Receives Japan Patent Allowance for CyPath Lung Early Lung Cancer Test
--------------------------------------------------------------------------------

- Japan Patent Office issued a Notice of Allowance for bioAffinity's method of predicting lung cancer likelihood using the CyPath Lung test and AI-built algorithm.
- Patent would be the first awarded in Japan for CyPath Lung and the fifth protecting the early lung cancer test in Asia, including China and Hong Kong.
- bioAffinity's portfolio includes 22 awarded U.S. and foreign patents and 36 pending applications; issuance expected after payment of applicable fee.
- CEO Maria Zannes said the patent strengthens IP protection in Asian markets; CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy, and 99% NPV.
- Company trades on Nasdaq Capital Market under BIAF for common stock and BIAFW for warrants to purchase common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046266/0001493152-26-046266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046266/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer